Angiodevice International Gmbh

Resurge Therapeutics Inc.

Cohesion Technologies, Inc.

Angiotech Pharmaceuticals (us), Inc.

Abbott Cardiovascular Systems, Inc.

Other

Canon Kabushiki Kaisha

Advanced Cardiovascular Systems, Inc.

Angiotech Pharmaceuticals, Inc.

Olof Mikael Trollsas

Jacqueline Anne Schroeder

Louis C Sehl

Donald G Wallace

David M Gravett

George Y Daniloff

Frank A DeLustro

Philip Michael Toleikis

John J Stankus

Shahram Shawn Gholami

George H Chu

David Toman

Eugene T Michal

Shubhayu Basu

Michael Ngo

Theodore S Fahlen

Woonza M Rhee

Gregory M Cruise

Kris E Sahlstrom

George T Coker, Iii

Marcee M Maroney

Benjamyn Serna

Sopheak P Sam

Brian D Rittmann

Philip M Toleikis

Frank A Delustro

A method for treating a prostate comprising the steps of using a needle-syringe coupled to a dose delivery device. The dose delivery device comprises a housing, a holder configured to receive a first portion of the needle-syringe, and an arm at least partially extending from the housing. The arm includes a surface configured to engage a second portion of the needle-syringe. The dose delivery device further includes an actuation member movable with respect to the housing, a worm coupled to the actuation member, a worm gear engaged with the worm, and a pinion gear fixed to the worm gear and engaged with the arm. The arm moves along a translation axis in response to user actuation of the actuation member about a rotational axis.

Dosing delivery devices, systems, and methods

Minimally invasive treatment methods for benign prostatic hyperplasia (BPH) tissue. A system includes a sustained release formulation comprising a cytostatic or cytotoxic drug, and an applicator or delivery system for local delivery of a composition comprising or consisting essentially of the sustained release formulation to the prostate. The applicator containing the composition is characterized by a KIR value of between 40 and 400 Centipoise per unit area.

Apparatus for treating Benign Prostatic Hyperplasia

Treatments for benign prostatic hyperplasia

Treating benign prostatic hyperplasia

A minimally invasive treatment of benign prostatic hyperplasia (BPH) tissue. A system includes a sustained release formulation comprising a cytostatic or cytotoxic drug, and an applicator or delivery system for local delivery of a composition comprising or consisting essentially of the sustained release formulation to the prostate. A method includes introducing a composition into the prostate to achieve a sustained release of the cytostatic or cytotoxic drug over a period of between about 14 days and 12 months.

System and method for prostate treatment

Multifunctional compounds are provided that readily crosslink in situ to provide crosslinked biomaterials. The multifunctional compounds contain a single component having at least three reactive functional groups thereon, with the functional groups selected so as to be non-reactive in an initial environment and inter-reactive in a modified environment. Reaction of a plurality of the multifunctional compounds results in a three-dimensional crosslinked matrix. In one embodiment, a first functional group is nucleophilic, a second functional group is electrophilic, and at least one additional functional group is nucleophilic or electrophilic. Methods for preparing and using the multifunctional compounds, and kits including the multifunctional compounds are also provided. Exemplary uses for the multifunctional compounds include tissue augmentation, biologically active agent delivery, bioadhesion, and prevention of adhesions following surgery or injury.

Kit for multifunctional compounds forming crosslinked biomaterials

The present invention relates generally to synthetic polymer compositions that form interpenetrating polymer networks. In a preferred embodiment, the compositions comprise two multifunctionally activated synthetic polymers, along with a tensile strength enhancer. Such compositions form matrices that exhibit superior cohesive strength and in many instances can serve as adequate replacements for surgical means of attaching tissues, such as sutures, sponges and medical staples.

Adhesive tissue repair patch and collagen sheets

Compositions, methods of manufacture and methods of treatment for post-myocardial infarction are herein disclosed. In some embodiments, the composition includes at least two components. In one embodiment, a first component can include a first functionalized polymer and a substance having at least one cell adhesion site combined in a first buffer at a pH of approximately 6.5. A second component can include a second buffer in a pH of between about 7.5 and 9.0. A second functionalized polymer can be included in the first or second component. In some embodiments, the composition can include at least one cell type and/or at least one growth factor. In some embodiments, the composition(s) of the present invention can be delivered by a dual bore injection device to a treatment area, such as a post-myocardial infarct region.

Modified two-component gelation systems, methods of use and methods of manufacture

Multifunctional compounds for forming crosslinked biomaterials and methods of preparation and use

Methods of preventing adhesion between issues are provided that utilizes in situ crosslinked biomaterials. The biomaterial contains at least the crosslinked product of two biocompatible, non-immunogenic components having reactive groups thereon, with the functional groups selected so as to enable inter-reaction between the components, i.e., crosslinking. Exemplary uses for the crosslinked compositions include preventing adhesions following surgery or injury, and preventing scar tissue formation.

Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use

Kits comprising dry power compositions are provided that readily crosslink in situ to provide crosslinked biomaterials. The dry powder composition contains at least two biocompatible, non-immunogenic components having reactive groups thereon, with the functional groups selected so as to enable inter-reaction between the components, i.e., crosslinking. Exemplary uses for the crosslinked biomaterials include tissue augmentation, biologically active agent delivery, bioadhesion, and prevention of adhesions following surgery or injury.

A method of tissue repair is provided using a biocompatible nonimmunogenic adhesive composition. The adhesive composition comprises collagen and a plurality of crosslinkable components having reactive functional groups thereon, with the functional groups selected so as to enable inter-reaction between the components, i.e., crosslinking. Kits for use in carrying out the method of the invention are also provided, as are pretreated surgically acceptable patches that have been coated with the aforementioned adhesive composition.

Adhesive tissue repair patch

Growing community of inventors

San Jose, CA, United States of America

Olof Mikael Trollsas